Brown, Lisle/Cummings’s Biogen BIIB Stock Holding History

Brown, Lisle/Cummings’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-1	Closed	-$137	–	776
2025 Q1	$137	Buy	+1	New	+$143	﹤0.01%	779

Other funds holding BIIB

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Brown, Lisle/Cummings's BIIB Position: Q2 2025 in Review

Brown, Lisle/Cummings sold out of Biogen (BIIB) in Q2 2025, closing a stake of 1 share — an estimated $137 sold.

Brown, Lisle/Cummings first reported a position in BIIB in Q1 2025 and held it in 1 quarter. The position peaked at $137 in Q1 2025. 866 funds tracked by Wall St. Rank hold BIIB as of Q2 2025.

Brown, Lisle/Cummings reported no remaining Biogen position as of Q2 2025 after selling out during the quarter.
Brown, Lisle/Cummings sold 1 Biogen share in Q2 2025, an estimated $137.
Brown, Lisle/Cummings first reported a position in Biogen in Q1 2025 and held it in 1 quarter.
Brown, Lisle/Cummings's Biogen position peaked at $137 in Q1 2025.
866 funds tracked by Wall St. Rank held Biogen as of Q2 2025.

Based on Brown, Lisle/Cummings's 13F filing for Q2 2025, filed 16 Jul 2025.